This product is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients aged 6 years and older with a body weight of at least 15 kg. Limitations of Use： •Due to the risk of kernicterus, atazanavir sulfate capsules are not recommended for use in pediatric patients younger than 3 months of age. •In patients with prior atazanavir/ritonavir treatment experience, treatment should be guided by the number of baseline major protease inhibitor resistance mutations.
This product is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: 1. Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). 2. Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk.
